Premium
Interstitial granulomatous dermatitis following tocilizumab, a paradoxical reaction?
Author(s) -
Altemir Arcadi,
IglesiasSancho Maribel,
SolaCasas María de los Ángeles,
NovoaLamazares Luis,
FernándezFigueras Maite,
SallerasRedonnet Montse
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14207
Subject(s) - medicine , tocilizumab , granuloma annulare , immunoglobulin d , dermatology , immunology , granulomatous disease , granuloma , sarcoidosis , chronic granulomatous disease , antibody , rheumatoid arthritis , b cell
Interstitial granulomatous dermatitis (IGD) is a rare dermatosis generally seen in the setting of rheumatic diseases, but also hematological disorders, internal malignances, infections, or drug induced. Herein, we report an exceptional case of an IGD with a clear chronological association with tocilizumab onset and cessation in a patient with adult‐onset Still's disease. We review the granulomatous cutaneous reactions so far reported with this novel therapy: sarcoidosis, granuloma annulare, and IGD. Tocilizumab is a humanized anti‐interleukin 6 receptor monoclonal antibody useful for the treatment of various systemic inflammatory disorders. Lately, it has found useful also for granulomatous diseases such as giant cell arteritis and even a promising response in IGD. Therefore, we believe our case adds the possibility of an IGD presenting as a paradoxical reaction.